BACKGROUND: Drug-resistant Mycobacterium tuberculosis has emerged as a global threat. In resource-constrained settings, patients with a history of tuberculosis (TB) treatment may have drug-resistant disease and may experience poor outcomes. There is a need to measure the extent of and risk factors for drug resistance in such patients. METHODS: From July 2003 through November 2006, we enrolled 410 previously treated patients with TB in Kampala, Uganda. We measured the prevalence of resistance to first- and second-line drugs and analyzed risk factors associated with baseline and acquired drug resistance. RESULTS: The prevalence of multidrug-resistant TB was 12.7% (95% confidence interval [95% CI], 9.6%-16.3%). Resistance to second-line drugs was low. Factors associated with multidrug-resistant TB at enrollment included a history of treatment failure (odds ratio, 23.6; 95% CI, 7.7-72.4), multiple previous TB episodes (odds ratio, 15.6; 95% CI, 5.0-49.1), and cavities present on chest radiograph (odds ratio, 5.9; 95% CI, 1.2-29.5). Among a cohort of 250 patients, 5.2% (95% CI, 2.8%-8.7%) were infected with M. tuberculosis that developed additional drug resistance. Amplification of drug resistance was associated with existing drug resistance at baseline (P < .01) and delayed sputum culture conversion (P < .01). CONCLUSIONS: The burden of drug resistance in previously treated patients with TB in Uganda is sizeable, and the risk of generating additional drug resistance is significant. There is an urgent need to improve the treatment for such patients in low-income countries.
BACKGROUND: Drug-resistant Mycobacterium tuberculosis has emerged as a global threat. In resource-constrained settings, patients with a history of tuberculosis (TB) treatment may have drug-resistant disease and may experience poor outcomes. There is a need to measure the extent of and risk factors for drug resistance in such patients. METHODS: From July 2003 through November 2006, we enrolled 410 previously treated patients with TB in Kampala, Uganda. We measured the prevalence of resistance to first- and second-line drugs and analyzed risk factors associated with baseline and acquired drug resistance. RESULTS: The prevalence of multidrug-resistant TB was 12.7% (95% confidence interval [95% CI], 9.6%-16.3%). Resistance to second-line drugs was low. Factors associated with multidrug-resistant TB at enrollment included a history of treatment failure (odds ratio, 23.6; 95% CI, 7.7-72.4), multiple previous TB episodes (odds ratio, 15.6; 95% CI, 5.0-49.1), and cavities present on chest radiograph (odds ratio, 5.9; 95% CI, 1.2-29.5). Among a cohort of 250 patients, 5.2% (95% CI, 2.8%-8.7%) were infected with M. tuberculosis that developed additional drug resistance. Amplification of drug resistance was associated with existing drug resistance at baseline (P < .01) and delayed sputum culture conversion (P < .01). CONCLUSIONS: The burden of drug resistance in previously treated patients with TB in Uganda is sizeable, and the risk of generating additional drug resistance is significant. There is an urgent need to improve the treatment for such patients in low-income countries.
Authors: M L Joloba; C C Whalen; D M Cave; K D Eisenach; J L Johnson; A Okwera; A Morrissey; S Bajaksouzian; J Feagin; R Mugerwa; J Ellner; M R Jacobs Journal: East Afr Med J Date: 2000-02
Authors: R S Wallis; M D Perkins; M Phillips; M Joloba; A Namale; J L Johnson; C C Whalen; L Teixeira; B Demchuk; R Dietze; R D Mugerwa; K Eisenach; J J Ellner Journal: Am J Respir Crit Care Med Date: 2000-04 Impact factor: 21.405
Authors: M A Espinal; K Laserson; M Camacho; Z Fusheng; S J Kim; R E Tlali; I Smith; P Suarez; M L Antunes; A G George; N Martin-Casabona; P Simelane; K Weyer; N Binkin; M C Raviglione Journal: Int J Tuberc Lung Dis Date: 2001-10 Impact factor: 2.373
Authors: T Yoshiyama; H Yanai; D Rhiengtong; P Palittapongarnpim; O Nampaisan; S Supawitkul; W Uthaivorawit; T Mori Journal: Int J Tuberc Lung Dis Date: 2004-01 Impact factor: 2.373
Authors: L Vásquez-Campos; L Asencios-Solis; E Leo-Hurtado; N Quispe-Torres; E Salazar-Lindo; J Bayona; M C Becerra Journal: Int J Tuberc Lung Dis Date: 2004-04 Impact factor: 2.373
Authors: Gilla Kaplan; Frank A Post; Andre L Moreira; Helen Wainwright; Barry N Kreiswirth; Melike Tanverdi; Barun Mathema; Srinivas V Ramaswamy; Gabi Walther; Lafras M Steyn; Clifton E Barry; Linda-Gail Bekker Journal: Infect Immun Date: 2003-12 Impact factor: 3.441
Authors: S K Sharma; K K Turaga; A Balamurugan; P K Saha; R M Pandey; N K Jain; V M Katoch; N K Mehra Journal: Infect Genet Evol Date: 2003-09 Impact factor: 3.342
Authors: Carlos Acuña-Villaorduña; Irene Ayakaka; Scott Dryden-Peterson; Susan Nakubulwa; William Worodria; Nancy Reilly; Jennifer Hosford; Kevin P Fennelly; Alphonse Okwera; Edward C Jones-López Journal: Am J Trop Med Hyg Date: 2015-05-04 Impact factor: 2.345
Authors: Benson R Kidenya; Lauren E Webster; Sehan Behan; Rodrick Kabangila; Robert N Peck; Stephen E Mshana; Oksana Ocheretina; Daniel W Fitzgerald Journal: Tuberculosis (Edinb) Date: 2013-09-07 Impact factor: 3.131
Authors: Alistair D Calver; Alecia A Falmer; Megan Murray; Odelia J Strauss; Elizabeth M Streicher; Madelene Hanekom; Thelma Liversage; Mothusi Masibi; Paul D van Helden; Robin M Warren; Thomas C Victor Journal: Emerg Infect Dis Date: 2010-02 Impact factor: 6.883
Authors: Danica Helb; Martin Jones; Elizabeth Story; Catharina Boehme; Ellen Wallace; Ken Ho; JoAnn Kop; Michelle R Owens; Richard Rodgers; Padmapriya Banada; Hassan Safi; Robert Blakemore; N T Ngoc Lan; Edward C Jones-López; Michael Levi; Michele Burday; Irene Ayakaka; Roy D Mugerwa; Bill McMillan; Emily Winn-Deen; Lee Christel; Peter Dailey; Mark D Perkins; David H Persing; David Alland Journal: J Clin Microbiol Date: 2009-10-28 Impact factor: 5.948
Authors: Sam Ogwang; Benon B Asiimwe; Hamidou Traore; Francis Mumbowa; Alphonse Okwera; Kathleen D Eisenach; Susan Kayes; Edward C Jones-López; Ruth McNerney; William Worodria; Irene Ayakaka; Roy D Mugerwa; Peter G Smith; Jerrold Ellner; Moses L Joloba Journal: BMC Infect Dis Date: 2009-08-26 Impact factor: 3.090